Shots: Sandoz will hold IPR of Humira in certain countries and will also pay royalties to AbbVie. In response AbbVie will not make any payments to Sandoz Humira’s license period […]readmore
Tags : Agreement
Shots: Sanofi and Evotec launches BRIDGE LAB031, designed to convert academic research into drug discovery candidates for multiple therapeutic areas. BRIDGE is a public-private partnership combining academia, biotech and venture […]readmore
Shots: The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional […]readmore
Shots: Celyad to get hold of Horizon’s shRNA technology for generation and development of allogenic CAR-T therapies shRNA (Short hairpin) technology is based on DNA and contains a selectable marker […]readmore
Shots: United States Army Medical Research Institute of Chemical Defense (USAMRICD) and Eagle collaborates for evaluating the neuroprotective effects of Ryanodex Eagle will bear the research study cost and will […]readmore
Shots: The collaboration is focused on developing technology for neoantigen-reactive T cell receptors (TCRs) to treat cancers, including solid tumor HiFiBio to get an upfront $10M with additional milestones payments […]readmore
Shots: Novartis out-licensed worldwide rights for its three drug candidates, including LYS228 & IID572 targeting carbapenem-resistant enterobacteriaceae (CRE) and MAK181 targeting Pseudomonas infections. Boston to pay an upfront, milestone and […]readmore
Shots: Hitachi Chemical’s subsidiary HCATS (Hitachi Chemical Advanced Therapeutics Solutions), will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials The agreement focuses on […]readmore
Shots: The termination is based on results from P-IIb study, assessing Novexatin vs PBO, which was unable to meet a main goal of study under FDA guidelines with no superiority […]readmore
Shots: Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct […]readmore